IDEAYA Biosciences, Inc. (IDYA) | Investment Case

1. Company Snapshot

1.a. Company Description

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability.

The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc.for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc.IDEAYA Biosciences, Inc.

was incorporated in 2015 and is headquartered in South San Francisco, California.

Show Full description

1.b. Last Insights on IDYA

Breaking News: IDEAYA Biosciences Inc reported no recent earnings release on February 18 2026. The company presented at Citi's 2026 Virtual Oncology Leadership Summit. There is no specific news or financials provided in the transcript. Analysts recommendations are not available. Some analysts have a hold rating on the stock. IDEAYA Biosciences Inc has several pipeline projects. The company is working on IDE161 and other assets. No detailed financial guidance is provided. IDEAYA Biosciences Inc focuses on oncology.

1.c. Company Highlights

Last Price	31.98
Change Percentage	-2.80%
Open	32.9
Previous Close	32.9
Market Cap ( Millions)	2804
Volume	805701
Year High	39.28
Year Low	13.45
M A 50	34.17
M A 200	27.58

FCF Yield	-2.62%
Dividend Yield	0.00%
ROE	-11.10%
Debt / Equity	5.42%
Net Debt / EBIDTA	47.62%
Price To Book	2.77
Price Earnings Ratio	-24.92
Price To FCF	-38.16
Price To sales	12.82
EV / EBITDA	-22.81

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Feb -21

Source: defenseworld.net

IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Feb -18

Source: seekingalpha.com

IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Feb -17

Source: prnewswire.com

IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events

Feb -02

Source: prnewswire.com

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jan -30

Source: prnewswire.com

General American Investors Co. Inc. Raises Stock Position in IDEAYA Biosciences, Inc. $IDYA

Jan -27

Source: defenseworld.net

IDEAYA Biosciences, Inc. (IDYA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan -13

Source: seekingalpha.com

IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference

Jan -11

Source: prnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (30.00%)

6. Segments

Research and Development for Oncology-Focused Precision Medicine

Expected Growth: 30.0%

The oncology-focused precision medicine market is rapidly expanding, driven by increasing demand for targeted therapies and advancements in genomic research. IDEAYA's strong pipeline and innovative approach position it for significant growth, in line with the global revenue growth hypothesis of 30.0%. The company's expertise in synthetic lethality and epigenetics is expected to drive its success in this segment.

7. Detailed Products

Targeted Protein Degradation (TPD) Platform

A novel approach to drug discovery that utilizes small molecules to selectively degrade disease-causing proteins, offering a potential solution for previously undruggable targets.

E3 Ligase Modulators

Small molecule modulators that selectively engage E3 ubiquitin ligases to induce protein degradation, providing a new avenue for therapeutic intervention.

Cereblon Modulators

Small molecule modulators that selectively engage the Cereblon E3 ubiquitin ligase to induce protein degradation, offering a potential solution for hematological malignancies and other diseases.

Degrader Conjugates

A novel class of therapeutics that combine a targeting moiety with a degrader molecule, enabling the selective degradation of disease-causing proteins in specific cell types or tissues.

Protein Degradation Profiling Services

Comprehensive profiling services that enable the identification of optimal degrader molecules and E3 ligase targets for specific disease indications.

8. IDEAYA Biosciences, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

IDEAYA Biosciences, Inc. has a unique portfolio of precision medicine oncology products, which reduces the threat of substitutes.

Bargaining Power Of Customers

IDEAYA Biosciences, Inc. has a diverse customer base, but some large pharmaceutical companies have significant bargaining power.

Bargaining Power Of Suppliers

IDEAYA Biosciences, Inc. has a strong supply chain management system, which reduces the bargaining power of suppliers.

Threat Of New Entrants

The biotechnology industry is highly competitive, and new entrants with innovative products can pose a significant threat to IDEAYA Biosciences, Inc.

Intensity Of Rivalry

The biotechnology industry is highly competitive, and IDEAYA Biosciences, Inc. faces intense rivalry from established players and new entrants.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	0.46%
Debt Cost	8.31%
Equity Weight	99.54%
Equity Cost	8.31%
WACC	8.31%
Leverage	0.46%

11. Quality Control: IDEAYA Biosciences, Inc. passed 3 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

BridgeBio Pharma

A-Score: 5.3/10

Value: 8.0

Growth: 5.1

Quality: 5.9

Yield: 0.0

Momentum: 10.0

Volatility: 3.0

1-Year Total Return ->

IDEAYA Biosciences

A-Score: 4.6/10

Value: 6.7

Growth: 2.9

Quality: 5.1

Yield: 0.0

Momentum: 9.0

Volatility: 3.7

1-Year Total Return ->

Alnylam Pharmaceuticals

A-Score: 4.5/10

Value: 0.0

Growth: 7.8

Quality: 4.7

Yield: 0.0

Momentum: 10.0

Volatility: 4.7

1-Year Total Return ->

Insmed

A-Score: 4.4/10

Value: 6.0

Growth: 3.3

Quality: 4.0

Yield: 0.0

Momentum: 10.0

Volatility: 3.0

1-Year Total Return ->

ADMA Biologics

A-Score: 4.0/10

Value: 1.3

Growth: 8.4

Quality: 8.5

Yield: 0.0

Momentum: 2.0

Volatility: 3.7

1-Year Total Return ->

Bio-Techne

A-Score: 3.5/10

Value: 0.9

Growth: 4.2

Quality: 6.3

Yield: 1.0

Momentum: 3.5

Volatility: 5.3

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

36.98%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

8.31%

IDEAYA Biosciences, Inc. - US45166A1025

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on IDYA

1.c. Company Highlights

Strong Momentum

Average Growth

Medium Volatility

Average Yield

Lower Growth

Earnings Miss

Stable Momentum

Earnings Beats

Average Quality

Weak Momentum

Revenues Beats

Fairly Valued

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (30.00%)

6. Segments

Research and Development for Oncology-Focused Precision Medicine

Expected Growth: 30.0%

7. Detailed Products

Targeted Protein Degradation (TPD) Platform

E3 Ligase Modulators

Cereblon Modulators

Degrader Conjugates

Protein Degradation Profiling Services

8. IDEAYA Biosciences, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: IDEAYA Biosciences, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

31.98$

Current Price

31.98$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA